title: Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.
abstract: HIV-1 primary infection is characterized by a short high titer viremia, which rapidly declines as the immune response emerges. The role of autologous neutralizing antibodies in the decline of viral replication was evaluated in 12 patients with primary or recent HIV-1 infection. Neutralizing antibodies detected for each patient could not generally be observed before several months after isolation of the first obtained HIV isolate. The plasma viral load, as measured by quantitation of the HIV-1 RNA, underwent a global decrease during the first 6 months of the infection, but this decrease did not seem to be associated with the emergence of neutralizing antibodies. The proviral load in peripheral blood mononuclear cells, which was studied by quantitative DNA polymerase chain reaction, exhibited fluctuations and was not as well curtailed as the plasma viremia in the majority of patients.
authors.affiliation: Laboratoire de Virologie, CHU de Bordeaux, France.
authors.forename: I
authors.initials: I
authors.lastname: Pellegrin
authors.forename: E
authors.initials: E
authors.lastname: Legrand
authors.forename: D
authors.initials: D
authors.lastname: Neau
authors.forename: P
authors.initials: P
authors.lastname: Bonot
authors.forename: B
authors.initials: B
authors.lastname: Masquelier
authors.forename: J L
authors.initials: JL
authors.lastname: Pellegrin
authors.forename: J M
authors.initials: JM
authors.lastname: Ragnaud
authors.forename: N
authors.initials: N
authors.lastname: Bernard
authors.forename: H J
authors.initials: HJ
authors.lastname: Fleury
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D016384:Consensus Sequence; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D015726:Giant Cells / Q000166:cytology; D015483:HIV Antibodies / Q000096:biosynthesis* / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007700:Kinetics; D007963:Leukocytes, Mononuclear / Q000821:virology; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000737:chemistry / Q000235:genetics; D011533:Proviruses / Q000235:genetics / Q000276:immunology / Q000502:physiology; D012367:RNA, Viral / Q000097:blood; D014766:Viremia / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D012367:RNA, Viral; D015215:Zidovudine